Product Information
CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.8024 per EA under NDC 16571069301. Its NADAC has been published 198 times since Dec 21, 2022.
FDA first approved this application on Jan 25, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
37.5; 200; 150 mg/1; mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571069301
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; ENTACAPONE; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA213212FDA Approved
1/25/2022
TE Code
AB
On Market Since
8/5/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has been published 198 times since Dec 21, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8024 per EA |
|---|---|
| All-time high | $0.9770 (Dec 11, 2024) |
| All-time low | $0.5695 (Oct 18, 2023) |
| 52-week high | $0.8235 |
| 52-week low | $0.6401 |
| Median price | $0.7664 |
| Average price | $0.7784 |
| Largest weekly change | -36.5% (Oct 18, 2023) |
| Weeks tracked | 198 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA, LEVODOPA AND ENTACAPONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CARBIDOPA, LEVODOPA AND ENTACAPONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.8024 per EA (NDC 16571069301), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has held within roughly two percent of its current level. It has been tracked across 198 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
Since Dec 21, 2022, the NADAC for CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB has ranged from a low of $0.5695 (Oct 18, 2023) to a high of $0.9770 (Dec 11, 2024), with a median of $0.7664 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB?
CARBIDOPA-LEVODOPA-ENTACAPONE 37.5-150-200 MG TAB (NDC 16571069301) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.